AQR Capital Management
GLUE icon

AQR Capital Management’s Monte Rosa Therapeutics GLUE Stock Holding History

AQR Capital Management’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.8M Sell
658,483
-126,574
-16% -$2.42M 0.01% 1303
2025
Q4 		$12.3M Buy
785,057
+67,795
+9% +$914K 0.01% 1120
2025
Q3 		$5.31M Sell
717,262
-566,680
-44% -$3M ﹤0.01% 1421
2025
Q2 		$5.79M Buy
1,283,942
+1,054,406
+459% +$4.7M ﹤0.01% 1202
2025
Q1 		$1.07M Buy
+229,536
New +$1.41M ﹤0.01% 1978

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

AQR Capital Management's GLUE Position: Q1 2026 in Review

AQR Capital Management reduced its Monte Rosa Therapeutics (GLUE) stake by 16% in Q1 2026, selling an estimated $2.42M and leaving 658,483 shares worth $10.8M. The position accounts for 0.01% of the portfolio, ranked #1303.

AQR Capital Management first reported a position in GLUE in Q1 2025 and has held it in 5 quarters since. The position peaked at $12.3M in Q4 2025. 190 funds tracked by Wall St. Rank hold GLUE as of Q1 2026.

  • AQR Capital Management held 658,483 shares of Monte Rosa Therapeutics worth $10.8M as of Q1 2026.
  • AQR Capital Management sold 126,574 Monte Rosa Therapeutics shares in Q1 2026, an estimated $2.42M.
  • Monte Rosa Therapeutics made up 0.01% of AQR Capital Management's portfolio in Q1 2026, its #1303 holding.
  • AQR Capital Management first reported a position in Monte Rosa Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • AQR Capital Management's Monte Rosa Therapeutics position peaked at $12.3M in Q4 2025.
  • 190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2026.

Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.